多囊卵巢综合征在绝经过渡期及绝经后的表现:系统综述与Meta分析
该系统综述与Meta分析纳入37项研究(其中28项进入定量合成),比较≥45岁围绝经期或绝经后多囊卵巢综合征(PCOS)女性与对照女性的雄激素、代谢及心血管指标,发现PCOS患者总睾酮、游离雄激素指数、雄烯二酮升高而性激素结合球蛋白降低,体重、胰岛素抵抗指标、糖尿病和高血压风险增加,但研究间异质性显著且证据质量总体偏低。
要点
- 围绝经期及绝经后PCOS女性总睾酮、游离雄激素指数和雄烯二酮均高于对照,性激素结合球蛋白降低。
- PCOS女性BMI、腰围、腰臀比、胰岛素抵抗指标、空腹胰岛素、空腹血糖及糖尿病风险均高于对照。
- PCOS女性高血压风险增高,心肌梗死和卒中患病率较高,但心血管疾病整体风险与对照相似。
核心结论
- PCOS女性的高雄激素表现似乎在晚育龄期及绝经后持续存在;多数心血管代谢合并症由体重超标与PCOS常共存所驱动,凸显针对该人群肥胖管理的重要性;但研究间显著异质性和证据总体质量低使无法得出确切结论,仍需基于足够把握度的前瞻性研究制定指南。
研究设计与样本
- 系统综述与Meta分析,检索截至2023年4月15日发表在Entrez-PubMed、EMBASE和Scopus的研究,纳入报告≥45岁围绝经期或绝经后PCOS患者与对照女性数据的横断面或前瞻性研究,由三名独立研究者提取数据,定量数据采用随机效应模型,并用GRADE系统评估证据质量。
- 初检识别1400篇文章,从纳入文章参考文献中另纳入6篇,删除476篇重复文献,因不同原因排除868篇,最终37篇有效研究纳入定性合成,其中28项研究(发表在41篇文章中)纳入定量合成与Meta分析,另9项研究仅纳入定性分析。
主要发现
- 与对照相比,围绝经期及绝经后PCOS患者循环总睾酮升高(标准化均数差SMD 0.78(0.35, 1.22))、游离雄激素指数升高(SMD 1.29(0.89, 1.68))、雄烯二酮升高(SMD 0.58(0.23, 0.94)),而性激素结合球蛋白降低(SMD -0.60(-0.76, -0.44))。
- PCOS女性较对照BMI升高(SMD 0.57(0.32, 0.75))、腰围增加(SMD 0.64(0.42, 0.86))、腰臀比增加(SMD 0.38(0.14, 0.61)),同时稳态模型胰岛素抵抗指数升高(SMD 0.56(0.27, 0.84))、空腹胰岛素升高(SMD 0.61(0.38, 0.83))、空腹血糖升高(SMD 0.48(0.29, 0.68)),糖尿病比值比升高(OR 3.01(1.91, 4.73))。
- PCOS女性较对照高密度脂蛋白胆固醇降低(SMD -0.32(-0.46, -0.19))、甘油三酯升高(SMD 0.31(0.16, 0.46)),而总胆固醇和低密度脂蛋白胆固醇浓度及血脂异常OR与对照相似;高血压OR在PCOS女性中升高(OR 1.79(1.36, 2.36))。
- 心肌梗死(OR 2.51(1.08, 5.81))和卒中(OR 1.75(1.03, 2.99))在PCOS女性中较对照更常见,但心血管疾病整体、冠状动脉疾病整体、乳腺癌及绝经年龄的OR在患者与对照间相似。
- 当Meta分析限制于PCOS女性与对照平均BMI相似的研究时,唯一保留统计学意义的差异是PCOS女性高密度脂蛋白胆固醇浓度降低;在两项绝经后PCOS女性与对照BMI相似的研究中,患者血清雄激素浓度升高,提示高雄激素在绝经后持续存在且与肥胖无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入研究间存在显著异质性,且此处汇集证据的总体质量低,使无法就该问题得出确切结论。
- 仍需基于足够把握度的前瞻性研究制定指南,以适当管理这些女性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current knowledge about the consequences of PCOS during the late reproductive years and after menopause is limited. OBJECTIVE AND RATIONALE: We performed a systematic review and meta-analysis of data on the pathophysiology, clinical manifestations, diagnosis, prognosis, and treatment of women ≥45 years of age-peri- or postmenopausal-with PCOS. SEARCH METHODS: Studies published up to 15 April 2023, identified by Entrez-PubMed, EMBASE, and Scopus online facilities, were considered. We included cross-sectional or prospective studies that reported data from peri- or postmenopausal patients with PCOS and control women with a mean age ≥45 years. Three independent researchers performed data extraction. Meta-analyses of quantitative data used random-effects models because of the heterogeneity derived from differences in study design and criteria used to define PCOS, among other confounding factors. Sensitivity analyses restricted the meta-analyses to population-based studies, to studies including only patients diagnosed using the most widely accepted definitions of PCOS, only menopausal women or only women not submitted to ovarian surgery, and studies in which patients and controls presented with similar indexes of weight excess. Quality of evidence was assessed using the GRADE system. OUTCOMES: The initial search identified 1400 articles, and another six were included from the reference lists of included articles; 476 duplicates were deleted. We excluded 868 articles for different reasons, leaving 37 valid studies for the qualitative synthesis, of which 28 studies-published in 41 articles-were considered for the quantitative synthesis and meta-analyses. Another nine studies were included only in the qualitative analyses. Compared with controls, peri- and postmenopausal patients with PCOS presented increased circulating total testosterone (standardized mean difference, SMD 0.78 (0.35, 1.22)), free androgen index (SMD 1.29 (0.89, 1.68)), and androstenedione (SMD 0.58 (0.23, 0.94)), whereas their sex hormone-binding globulin was reduced (SMD -0.60 (-0.76, -0.44)). Women with PCOS showed increased BMI (SMD 0.57 (0.32, 0.75)), waist circumference (SMD 0.64 (0.42, 0.86)), and waist-to-hip ratio (SMD 0.38 (0.14, 0.61)) together with increased homeostasis model assessment of insulin resistance (SMD 0.56 (0.27, 0.84)), fasting insulin (SMD 0.61 (0.38, 0.83)), fasting glucose (SMD 0.48 (0.29, 0.68)), and odds ratios (OR, 95% CI) for diabetes (OR 3.01 (1.91, 4.73)) compared to controls. Women with PCOS versus controls showed decreased HDL concentrations (SMD -0.32 (-0.46, -0.19)) and increased triglycerides (SMD 0.31 (0.16, 0.46)), even though total cholesterol and LDL concentrations, as well as the OR for dyslipidaemia, were similar to those of controls. The OR for having hypertension was increased in women with PCOS compared with controls (OR 1.79 (1.36, 2.36)). Albeit myocardial infarction (OR 2.51 (1.08, 5.81)) and stroke (OR 1.75 (1.03, 2.99)) were more prevalent in women with PCOS than controls, the ORs for cardiovascular disease as a whole, coronary artery disease as a whole, breast cancer and age at menopause, were similar in patients and controls. When restricting meta-analysis to studies in which women with PCOS and controls had a similar mean BMI, the only difference that retained statistical significance was a decrease in HDL-cholesterol concentration in the former and, in the two studies in which postmenopausal women with PCOS and controls had similar BMI, patients presented with increased serum androgen concentrations, suggesting that hyperandrogenism persists after menopause, regardless of obesity. WIDER IMPLICATIONS: Hyperandrogenism appeared to persist during the late-reproductive years and after menopause in women with PCOS. Most cardiometabolic comorbidities were driven by the frequent coexistence of weight excess and PCOS, highlighting the importance of targeting obesity in this population. However, the significant heterogeneity among included studies, and the overall low quality of the evidence gathered here, precludes reaching definite conclusions on the issue. Hence, guidelines derived from adequately powered prospective studies are definitely needed for appropriate management of these women.
引用
- Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, et al. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update. 2023. PMID: 37353908. doi:10.1093/humupd/dmad015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。